Drugs / GATE-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04618263 | Oct 2020 → Aug 2021 | hypersomnia, major depressive disorder | Syndeio Biosciences, Inc | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GATE-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04618263 ↗ |
| Action | Inhibit | “GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist” NCT04618263 ↗ |
| Route | Intravenous | “intravenously (IV) administered GATE-101” NCT04618263 ↗ |